Guardant Health, Inc. provided revenue guidance for the year 2022. The company continues to expect full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.58 USD | +1.75% | +8.28% | -31.31% |
29/04 | Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating | MT |
22/04 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.31% | 2.26B | |
-18.16% | 11.13B | |
+58.43% | 3.6B | |
-14.31% | 2.16B | |
-26.61% | 1.54B | |
+34.35% | 1.17B | |
-3.28% | 744M | |
-22.75% | 482M | |
-40.20% | 432M | |
+17.30% | 357M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Provides Revenue Guidance for the Year 2022